Abstract: Immunohistochemistry (IHC) examination is essential to determine the tumour subtypes, provide key prognostic factors, and develop personalized treatment plans for breast cancer. However, ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

This study investigates the variability in cancer diagnosis across different tissues and organs, with a focus on the role of diagnostic methods such as Hematoxylin and Eosin (H&E) staining and ...

According to Lunit, patients identified by the AI model as having a high proportion of HER2 IHC 3+ tumour cells exhibited better clinical outcomes than those identified through traditional HER2 ...

[18] Although it is not mandatory to follow the guidelines, they certainly are of utmost help to all surgical or molecular pathology laboratories that perform HER2 testing in their daily practice.

Immunohistochemistry (IHC) antibodies targeting CD56, MYOD1, DESMIN and MYOGENIN were used to evaluate the RMS phenotype of the tumors. The stained tissue sections were rated by a pathologist for the ...

Datroway is approved for HR-positive, HER2-negative breast cancer after prior endocrine and chemotherapy treatments. TROPION-Breast01 trial showed Datroway improved progression-free survival and ...